Zacks Investment Research downgraded shares of Catalent Inc (NASDAQ:CTLT) from a buy rating to a hold rating in a research report sent to investors on Friday.
According to Zacks, “Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. Catalent, Inc. is headquartered in Somerset, New Jersey. “
Other equities research analysts have also issued research reports about the stock. Needham & Company LLC assumed coverage on shares of Catalent in a report on Tuesday, September 12th. They issued a hold rating and a $42.00 price target on the stock. BidaskClub lowered shares of Catalent from a buy rating to a hold rating in a report on Friday, September 15th. Bank of America Corporation reissued a buy rating and issued a $38.00 price target (up previously from $37.00) on shares of Catalent in a report on Friday, July 21st. Piper Jaffray Companies reissued a buy rating and issued a $45.00 price target on shares of Catalent in a report on Tuesday, August 29th. Finally, ValuEngine raised shares of Catalent from a hold rating to a buy rating in a report on Thursday, September 7th. Five analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus target price of $41.67.
Shares of Catalent (CTLT) traded up $1.11 during trading hours on Friday, reaching $42.70. 910,929 shares of the company were exchanged, compared to its average volume of 1,150,000. Catalent has a one year low of $21.85 and a one year high of $43.39.
Catalent (NASDAQ:CTLT) last announced its quarterly earnings results on Monday, August 28th. The company reported $0.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.57 by $0.08. The business had revenue of $616.90 million for the quarter, compared to analyst estimates of $547.48 million. Catalent had a net margin of 10.02% and a return on equity of 36.29%. The company’s revenue was up 15.9% on a year-over-year basis. During the same quarter last year, the firm earned $0.52 EPS.
In other news, SVP Christine Dolan sold 1,594 shares of Catalent stock in a transaction dated Tuesday, August 29th. The shares were sold at an average price of $38.75, for a total transaction of $61,767.50. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Several institutional investors and hedge funds have recently made changes to their positions in CTLT. OppenheimerFunds Inc. lifted its position in Catalent by 29.2% during the 1st quarter. OppenheimerFunds Inc. now owns 18,737 shares of the company’s stock valued at $530,000 after acquiring an additional 4,237 shares during the period. Teachers Advisors LLC lifted its position in Catalent by 5.0% during the 1st quarter. Teachers Advisors LLC now owns 173,062 shares of the company’s stock valued at $4,901,000 after acquiring an additional 8,314 shares during the period. PNC Financial Services Group Inc. lifted its position in Catalent by 66.5% during the 1st quarter. PNC Financial Services Group Inc. now owns 6,070 shares of the company’s stock valued at $173,000 after acquiring an additional 2,425 shares during the period. Legal & General Group Plc lifted its position in Catalent by 46.4% during the 1st quarter. Legal & General Group Plc now owns 82,380 shares of the company’s stock valued at $2,335,000 after acquiring an additional 26,098 shares during the period. Finally, Vanguard Group Inc. lifted its position in Catalent by 3.2% during the 1st quarter. Vanguard Group Inc. now owns 9,749,905 shares of the company’s stock valued at $276,118,000 after acquiring an additional 303,213 shares during the period.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
What are top analysts saying about Catalent Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Catalent Inc and related companies.